Name

Vandetanib

Alternate Names

AZD6474
Caprelsa
Zactima
ZD 6474
ZD-6474
ZD6474

Abbreviations

None

Category

Chemotherapy

Subcategory

Angiogenesis inhibitor

NSC Number

None

Primary Site

Breast
cervical
endometrial
ovarian
prostate
Thyroid

Histology

None

Remarks

April 6, 2011: Received FDA approval for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.
Phase III Lung
Vascular endothelial cell growth factor receptor tyrosine kinase (VEGFR TKI) inhibitor. AstraZeneca.

Coding

This drug should be coded
Glossary